Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + SOX in neoadjuvant gastric cancer
NCT05948449Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Jul 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Sichuan University. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05948449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948449.